Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)/Astellas Pharma Inc. Collaboration

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These grants were made possible through a research grant from AVEO Oncology and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs in the treatment of solid tumors.

Back to news